NCT06254066View on ClinicalTrials.gov

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2028

Conditions
Female Breast Cancer PatientsHistopathologically Confirmed Advanced HR +/HER2-invasive Breast CancerHRD Positive Advanced Breast Cancer
Interventions
DRUG

Adebrelimab plus Fluzoparib

Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer

All Listed Sponsors
collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Zhejiang Cancer Hospital

OTHER

NCT06254066 - Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer | Biotech Hunter | Biotech Hunter